Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
heat-treated lactobacillus johnsonii NCC 533
- Development stage
- Preclinical
- Lead developer
- Nestlé
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Topical, Oral
01
Overview
**Heat-treated lactobacillus johnsonii NCC 533** is a non-replicating, inactivated form of the probiotic strain L. johnsonii NCC 533 (also known as La1) produced by heat treatment. It is applied topically in cosmetic or therapeutic formulations for skin disorders, especially atopic dermatitis, and works by reducing Staphylococcus aureus colonization and stimulating the skin's innate immune system through upregulation of antimicrobial peptides such as β-defensins and cathelicidin. The mechanism involves microbial cell wall components that interact with pattern recognition receptors on host cells, enhancing endogenous antimicrobial defense independently of probiotic viability. This form is not considered a classical probiotic, as it is non-living, but exerts postbiotic effects, and is researched and developed for topical, and to some extent oral, use for prevention and adjunctive treatment of infectious and inflammatory disorders, including atopic dermatitis and potentially other conditions linked to impaired epithelial/mucosal defense.[1][3][4][5][7]
- Brand names
- La1La-1La 1
- Other names
- heat-killed lactobacillus johnsonii NCC 533non-replicating lactobacillus johnsonii NCC 533HT La1
02
Targets
TLR2 (Toll-like Receptor 2)
Beyond the preview
Go deeper on heat-treated lactobacillus johnsonii NCC 533.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on heat-treated lactobacillus johnsonii NCC 533.